Complement function in mAb-mediated cancer immunotherapy

Trends Immunol. 2004 Mar;25(3):158-64. doi: 10.1016/j.it.2004.01.008.
No abstract available

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Adjuvants, Immunologic / therapeutic use
  • Animals
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibody-Dependent Cell Cytotoxicity
  • Complement Activation / drug effects
  • Complement C3b / physiology
  • Complement Membrane Attack Complex / physiology
  • Complement System Proteins / physiology*
  • Cytotoxicity, Immunologic / drug effects
  • Drug Design
  • Glucans / pharmacology
  • Glucans / therapeutic use
  • Humans
  • Immunotherapy*
  • Macrophage-1 Antigen / immunology
  • Membrane Proteins / antagonists & inhibitors
  • Membrane Proteins / physiology
  • Mice
  • Models, Immunological
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Proteins / physiology
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Neoplasms, Experimental / immunology
  • Neoplasms, Experimental / therapy
  • beta-Glucans*

Substances

  • Adjuvants, Immunologic
  • Antibodies, Monoclonal
  • Complement Membrane Attack Complex
  • Glucans
  • Macrophage-1 Antigen
  • Membrane Proteins
  • Neoplasm Proteins
  • beta-Glucans
  • Complement C3b
  • Complement System Proteins
  • beta-1,3-glucan